News Roivant's new 'vant' emerges to advance Bayer lung drug Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.
News European Commission approves 2nd IPCEI to sum of €403m The European Commission has approved, under EU State aid rules, the second health-related IPCEI to support innovations in medical devices.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face